Huadong Medicine has made an announcement stating that the marketing authorization application for the adult long-term weight management indication of its semaglutide injection (HDM1702) has been accepted. This application was submitted by its fully-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. Semaglutide injection is a long-acting GLP-1 receptor agonist. Phase III clinical trials have demonstrated that its efficacy is on par with that of the original drug, and it boasts a favorable safety profile. The company has directly invested around RMB 85.51 million in the research and development of this project. The acceptance of this application signifies a notable advancement in R&D efforts and will contribute to bolstering the company's core competitiveness within the realm of endocrine therapy. In the meantime, the company cautions investors to be mindful of the investment risks stemming from uncertainties in the review and approval process.